-
PROVIDERS
REGISTER NOW
Scientific breakthroughs across the cancer continuum: Research from the 2024 ASCO® Annual Meeting
Join us as we engage in a multi-disciplinary discussion around practice changing approaches in patient management across the cancer care journey. -
LIFE SCIENCES
REGISTER NOW
Integrating omics in R&D: A new era of biomedical research
Join us as industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape. -
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Tempus xM MRD
Tumor-naïve MRD assay for ctDNA detection
xM MRD is a liquid-only approach to MRD assessment that detects trace amounts of residual ctDNA, leveraging both methylation and genomic variant MRD classifiers while applying algorithms that support filtering of artifacts, like CHIP and germline variants, to deliver a binary MRD call.
As a tumor-naïve assay with dual workflows, Tempus xM MRD offers several advantages to biopharma, including accelerated turnaround times as well as the availability of variant-level information. xM MRD is currently available in stage II-III colorectal cancer. Tempus is actively seeking partners for indication expansion for this assay.
SOPHISTICATED MRD MODEL
Harnessing the power of a dual workflow
xM MRD leverages both variant and methylation workflows to call MRD+/-, bringing forward variant-level data about your patient cohort.*
Faster TAT
As a tumor-naïve assay, xM MRD reduces operational research delays due to tissue procurement.
Data-informed model
The xM MRD algorithmic model was developed using Tempus’ robust multimodal database, leveraging known tumor profiles and clinical outcomes to correct for CHIP and germline confounders.
Valuable insights with every sample
xM MRD utilizes both methylation and variant workflows to call MRD+/-, helping to bring forward variant level data on cohorts.*
Our Science
Longitudinal clinical performance of a novel tumor-naïve minimal residual disease assay in resected stage II and III colorectal cancer patients: A subset analysis from the GALAXY study in CIRCULATE-JapanxM MRD results predict disease-free survival (DFS) nearly 5 times superior to standard of care carcinoembryonic antigen (CEA) (adjusted hazard ratio 9.69 vs. 2.13).
LEARN MORE
Parternship Opportunities
Strategic validation studies with flexible opportunities for additional indications
Colorectal Cancer (CRC)
Tempus xM MRD is clinically validated¹ for early stage (II and III) colorectal cancer and reports on robust variant gene data specific to this indication.
Custom models
For indications outside of colorectal cancer, we are excited to collaborate with biopharma partners and build custom models.
ctDNA Suite
Tempus offers a comprehensive liquid portfolio to support drug development, including patient stratification for future trials, clinical trial design, and treatment response monitoring. Tempus xM Monitor (ctDNA tumor fraction calculation & monitoring) is currently available for biopharma partners for research use only.
-
TEMPUS xM MRD
MRD Detection
A tumor-naïve assay that detects ctDNA in patients following curative-intent treatment to identify patients at high risk of recurrence. Currently available in early stage (II and III) colorectal cancer.
LEARN MORE -
TEMPUS xM MONITOR
ctDNA Tumor Fraction Calculation and Monitoring
A ctDNA assay which measures changes in ctDNA tumor fraction to provide information on early response to immunotherapy for patients with advanced cancers. Currently available for research use only.
LEARN MORE -
TEMPUS xF+
523 Gene Liquid Assay
A ctDNA seq panel that interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help clinicians identify treatment opportunities. Identifies SNV, insertions / deletions, CNVs, gene rearrangements from select genes, as well as MSI and bTMB.
LEARN MORE -
TEMPUS xF
105 Gene Liquid Assay
A ctDNA seq panel that detects oncogenic drivers and resistance mutations, assesses for MSI, and identifies SNVs, INDELs, and CNVs.
LEARN MORE
MRD Detection
A tumor-naïve assay that detects ctDNA in patients following curative-intent treatment to identify patients at high risk of recurrence. Currently available in early stage (II and III) colorectal cancer.
LEARN MOREctDNA Tumor Fraction Calculation and Monitoring
A ctDNA assay which measures changes in ctDNA tumor fraction to provide information on early response to immunotherapy for patients with advanced cancers. Currently available for research use only.
LEARN MORE523 Gene Liquid Assay
A ctDNA seq panel that interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help clinicians identify treatment opportunities. Identifies SNV, insertions / deletions, CNVs, gene rearrangements from select genes, as well as MSI and bTMB.
LEARN MORE105 Gene Liquid Assay
A ctDNA seq panel that detects oncogenic drivers and resistance mutations, assesses for MSI, and identifies SNVs, INDELs, and CNVs.
LEARN MORE1 Nakamura, Y., et al. A tumor-uninformed ctDNA assay detecting MRD in patients with resected stage II or III colorectal cancer predicts recurrence: Subset analysis from the GALAXY study in CIRCULATE-Japan. Presented at ASCO GI 2024.
*Dual methylation and variant workflows are utilized at the landmark timepoint (LMT) only, all subsequent timepoints utilize the methylation workflow only.
This is data-driven precision medicine
This is the future of healthcare.